Table 1. Demographic, disease, and treatment characteristics.
| Characteristic | Value |
|---|---|
| Sex, n (%), N=226† | |
| Female | 52 (23.0) |
| Male | 174 (77.0) |
| Race, n (%), N=226 | |
| American Indian | 1 (0.4) |
| Asian | 39 (17.3) |
| Black | 27 (11.9) |
| Hispanic | 20 (8.8) |
| White | 133 (58.8) |
| Other | 6 (2.7) |
| Age at first SIRT, years, N=226 | |
| Mean (SD) | 65.1 (9.42) |
| Range | 40.3–85.2 |
| <70, n (%) | 156 (69.0) |
| ≥70, n (%) | 70 (31.0) |
| HCC etiology, n (%), N=224‡ | |
| Hepatitis C | 138 (61.6) |
| Alcohol use | 45 (20.1) |
| NASH | 27 (12.1) |
| Hepatitis B | 17 (7.6) |
| Cryptogenic | 15 (6.7) |
| Other§ | 7 (3.1) |
| MELD score, N=218 | |
| Mean (SD) | 8.8 (2.2) |
| ≤10, n (%) | 162 (74.3) |
| >15, n (%) | 1 (0.5) |
| ALBI score, mean (SD) | –2.3 (0.57) |
| Child-Pugh grade, n (%), N=150 | |
| A | 110 (73.3) |
| B | 37 (24.7) |
| C | 3 (2.0) |
| Target lesion size, cm, N=114 | |
| Mean (SD) | 6.8 (4.4) |
| Median (IQR) | 5.8 (5.4) |
| Range | 0.6–30.1 |
| Bilobar disease, n (%), N=221 | 105 (47.5) |
| Portal vein thrombosis, n (%), N=204 | 44 (21.6) |
| Ascites, n (%), N=211 | 71 (33.7) |
| Laboratory values, mean (SD) | |
| Bilirubin, mg/dL, N=226 | 1.1 (0.5) |
| Albumin, g/dL, N=224 | 3.6 (0.6) |
| Creatinine, mg/dL, N=220 | 0.9 (0.3) |
| INR, N=219 | 1.1 (0.2) |
| Previous treatments, n (%), N=179¶ | |
| Any treatment | 131 (73.2) |
| Transarterial chemoembolization | 74 (41.3) |
| Sorafenib | 40 (22.4) |
| Ablation | 25 (14.0) |
| Resection | 21 (11.7) |
| Radiation | 2 (1.1) |
| Y-90 resin treatments, n (%), N=226 | |
| 1 | 157 (69.5) |
| 2 | 55 (24.3) |
| 3 | 10 (4.4) |
| 4 | 4 (1.8) |
| Mean (SD) | 1.4 (0.7) |
| Radiation dose of first SIRT, mCi, N=222 | |
| Mean (SD) | 1.18 (0.49) |
†, number of patients with available data is indicated; percentages are relative to the number with available data. ‡, some patients had >1 etiology. §, “other” includes autoimmune hepatitis, iron-overload cirrhosis, primary biliary cirrhosis, de novo HCC. ¶, some patients had >1 previous treatment. ALBI, albumin-bilirubin; HCC, hepatocellular carcinoma; INR, international normalized ratio; IQR, interquartile range; NASH, nonalcoholic steatohepatitis; max, maximum; MELD, model for end-stage liver disease; min, minimum; SD, standard deviation; SIRT, selective internal radiation therapy; Y-90, yttrium-90.